LONDON – Armed with the results of a Phase I/II trial in which its light-mediated chemotherapy product induced complete regression in all evaluable tumors, PCI Biotech A/S has raised NOK90 million (US$14. 1 million) in an oversubscribed round to fund a Phase II/III registration trial in head and neck cancers. (BioWorld International) Read More
